These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 35067961)

  • 21. Target therapy for BRAF mutated anaplastic thyroid cancer: a clinical and molecular study.
    da Silva TN; Rodrigues R; Saramago A; Pires C; Rito M; Horta M; Martins C; Leite V; Cavaco BM
    Eur J Endocrinol; 2023 Jan; 188(1):. PubMed ID: 36651156
    [TBL] [Abstract][Full Text] [Related]  

  • 22. BRAF Inhibition in BRAFV600E-Positive Anaplastic Thyroid Carcinoma.
    Lim AM; Taylor GR; Fellowes A; Cameron L; Lee B; Hicks RJ; McArthur GA; Angel C; Solomon B; Rischin D
    J Natl Compr Canc Netw; 2016 Mar; 14(3):249-54. PubMed ID: 26957611
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of MEK Signaling Attenuates Cancer Stem Cell Activity in Anaplastic Thyroid Cancer.
    Kimura T; Doolittle WKL; Kruhlak M; Zhao L; Hwang E; Zhu X; Tang B; Wolcott KM; Cheng SY
    Thyroid; 2024 Apr; 34(4):484-495. PubMed ID: 38115586
    [No Abstract]   [Full Text] [Related]  

  • 24. Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer.
    Subbiah V; Kreitman RJ; Wainberg ZA; Cho JY; Schellens JHM; Soria JC; Wen PY; Zielinski C; Cabanillas ME; Urbanowitz G; Mookerjee B; Wang D; Rangwala F; Keam B
    J Clin Oncol; 2018 Jan; 36(1):7-13. PubMed ID: 29072975
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Surgery After BRAF-Directed Therapy Is Associated with Improved Survival in BRAF
    Zhao X; Wang JR; Dadu R; Busaidy NL; Xu L; Learned KO; Chasen NN; Vu T; Maniakas A; Eguia AA; Diersing J; Gross ND; Goepfert R; Lai SY; Hofmann MC; Ferrarotto R; Lu C; Gunn GB; Spiotto MT; Subbiah V; Williams MD; Cabanillas ME; Zafereo ME
    Thyroid; 2023 Apr; 33(4):484-491. PubMed ID: 36762947
    [No Abstract]   [Full Text] [Related]  

  • 26. Detection of BRAFV600E by digital PCR on fine-needle aspirate enables rapid initiation of dabrafenib and trametinib in unresectable anaplastic thyroid carcinoma.
    Buffet C; Allard L; Guillerm E; Ghander C; Mathy E; Lussey-Lepoutre C; Julien N; Touma E; Quilhot P; Godiris-Petit G; Lacorte JM; Leenhardt L; Denis JA
    Eur J Endocrinol; 2022 Sep; 187(3):K33-K38. PubMed ID: 35900324
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dual Inhibition of BRAF-MAPK and STAT3 Signaling Pathways in Resveratrol-Suppressed Anaplastic Thyroid Cancer Cells with BRAF Mutations.
    Lu MD; Li H; Nie JH; Li S; Ye HS; Li TT; Wu ML; Liu J
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430869
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Laryngotracheal Resection After B-Raf Proto-oncogene Inhibition for Anaplastic Thyroid Carcinoma.
    Kent J; Erwin P; Haraf D; Liao CY; Durham J; Angelos P; Agrawal N; Baird BJ; Madariaga MLL
    Ann Thorac Surg; 2023 May; 115(5):e117-e120. PubMed ID: 35504360
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genomic Alterations of Anaplastic Thyroid Carcinoma Detected by Targeted Massive Parallel Sequencing in a BRAF(V600E) Mutation-Prevalent Area.
    Jeon MJ; Chun SM; Kim D; Kwon H; Jang EK; Kim TY; Kim WB; Shong YK; Jang SJ; Song DE; Kim WG
    Thyroid; 2016 May; 26(5):683-90. PubMed ID: 26980298
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Promising Therapeutic Targets for Recurrent/Metastatic Anaplastic Thyroid Cancer.
    Abdalla AS; Rahman M; Khan SA
    Curr Treat Options Oncol; 2024 Jul; 25(7):869-884. PubMed ID: 38862695
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluating new treatments for anaplastic thyroid cancer.
    Coca-Pelaz A; Rodrigo JP; Lopez F; Shah JP; Silver CE; Al Ghuzlan A; Menke-van der Houven van Oordt CW; Smallridge RC; Shaha AR; Angelos P; Mendenhall WM; Piazza C; Olsen KD; Corry J; Tufano RP; Sanabria A; Nuyts S; Nathan CA; Vander Poorten V; Dias FL; Suarez C; Saba NF; de Graaf P; Williams MD; Rinaldo A; Ferlito A
    Expert Rev Anticancer Ther; 2022 Nov; 22(11):1239-1247. PubMed ID: 36283091
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of BRAF/MEK inhibitors in BRAFV600E-mutated anaplastic thyroid cancer: a systematic review and meta-analysis.
    Priantti JN; Rodrigues NMV; de Moraes FCA; da Costa AG; Jezini DL; Heckmann MIO
    Endocrine; 2024 Oct; 86(1):284-292. PubMed ID: 38709445
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of dabrafenib and erlotinib combination treatment on anaplastic thyroid carcinoma.
    Choi YS; Kwon H; You MH; Kim TY; Kim WB; Shong YK; Jeon MJ; Kim WG
    Endocr Relat Cancer; 2022 May; 29(6):307-319. PubMed ID: 35343921
    [TBL] [Abstract][Full Text] [Related]  

  • 34. BRAF
    Traversi F; Stooss A; Dettmer MS; Charles RP
    Thyroid; 2021 May; 31(5):787-799. PubMed ID: 33012268
    [No Abstract]   [Full Text] [Related]  

  • 35. Interstitial lung disease associated with combination therapy of dabrafenib and trametinib in metastatic BRAF
    Zeng Q; Deng Y; Zhang L; Wang W
    Int J Clin Pharmacol Ther; 2022 May; 60(5):225-231. PubMed ID: 35072623
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recent advances in anaplastic thyroid cancer management.
    Hamidi S; Maniakas A
    Curr Opin Endocrinol Diabetes Obes; 2023 Oct; 30(5):259-264. PubMed ID: 37410453
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression of angiogenic switch, cachexia and inflammation factors at the crossroad in undifferentiated thyroid carcinoma with BRAF(V600E).
    Husain A; Hu N; Sadow PM; Nucera C
    Cancer Lett; 2016 Oct; 380(2):577-585. PubMed ID: 26189429
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Tyrosine Kinase Inhibitor Lenvatinib Inhibits Anaplastic Thyroid Carcinoma Growth by Targeting Pericytes in the Tumor Microenvironment.
    Iesato A; Li S; Sadow PM; Abbasian M; Nazarian A; Lawler J; Nucera C
    Thyroid; 2023 Jul; 33(7):835-848. PubMed ID: 37171127
    [No Abstract]   [Full Text] [Related]  

  • 39. Comprehensive genomic profiling from C-CAT database unveiled over 80% presence of oncogenic drivers in anaplastic thyroid carcinoma including BRAF, RAS family, NF1, and FGFR1.
    Saito Y; Kage H; Kobayashi K; Kamogashira T; Fukuoka O; Yamamura K; Yamashita S; Tanabe M; Oda K; Kondo K
    Clin Endocrinol (Oxf); 2024 Aug; 101(2):170-179. PubMed ID: 38853441
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neoadjuvant famitinib and camrelizumab, a new combined therapy allowing surgical resection of the primary site for anaplastic thyroid carcinoma.
    Yang S; Ji D; Xue F; Chen T; Wang Y; Ji Q
    Cancer Rep (Hoboken); 2023 Jan; 6(1):e1770. PubMed ID: 36535914
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.